Stanford researchers have discovered that tumors increase the risk of atherosclerosis by regulating expression of a specific gene that stimulates angiogenesis and intraplaque neovessel formation.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Researchers at Stanford have identified the use of the drug verteporfin to treat or reduce the risk of developing ibrosis after ocular procedures or ocular injury. Of interest is corneal injury, for example after refractive surgery or crosslinking, e.g.
Researchers at Stanford have developed innovative Verteporfin conjugates that considerably enhance the solubility and therapeutic potential of Verteporfin.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Researchers at Stanford have developed gene editing methods for modifying hematopoietic stem and progenitor cells (HSPCs) to express truncated forms of the erythropoietin receptor (tEPOR).
Stanford inventors have developed a method of using CRISPR/Cas9 or similar gene editing technologies to genetically edit an individual's own myeloid cells for specific gene targets, which are critical to wound repair, and applying these edited cells in a hydrogel to promote ra
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
Researchers in Prof. Stephen Quake's laboratory have developed a CRISPER-Cas-based targeted endonuclease system designed to treat latent viral infections by attacking the viral genome.
Researchers at Stanford have developed methods of using CRISPR/Cas9-mediated genome editing to treat patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Approximately 85% of lung cancers are NSCLC.
Researchers in Prof. Mark Kay's laboratory have developed recombinant adeno-associated viral (AAV) capsid proteins that transduce human primary hepatocytes at high efficiency in vitro and in vivo.